Bilcare Past Earnings Performance
Past criteria checks 2/6
Bilcare has been growing earnings at an average annual rate of 72.1%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 32.2% per year. Bilcare's return on equity is 5.8%, and it has net margins of 3.1%.
Key information
72.1%
Earnings growth rate
72.1%
EPS growth rate
Life Sciences Industry Growth | 11.2% |
Revenue growth rate | -32.2% |
Return on equity | 5.8% |
Net Margin | 3.1% |
Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bilcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7,806 | 239 | 635 | 0 |
30 Sep 23 | 8,515 | 119 | 654 | 0 |
30 Jun 23 | 9,156 | 138 | 644 | 0 |
31 Mar 23 | 9,815 | 150 | 649 | 0 |
31 Dec 22 | 10,037 | -370 | 642 | 0 |
30 Sep 22 | 9,656 | -321 | 632 | 0 |
30 Jun 22 | 9,151 | -40 | 619 | 0 |
31 Mar 22 | 8,447 | -126 | 619 | 0 |
31 Dec 21 | 7,648 | 49 | 607 | 0 |
30 Sep 21 | 7,135 | 58 | 589 | 0 |
30 Jun 21 | 6,617 | -200 | 577 | 0 |
31 Mar 21 | 6,227 | -211 | 571 | 0 |
31 Dec 20 | 5,671 | 438 | 683 | 0 |
30 Sep 20 | 7,432 | 981 | 1,127 | 0 |
30 Jun 20 | 12,650 | -325 | 2,429 | 0 |
31 Mar 20 | 18,270 | -1,035 | 3,868 | 0 |
31 Dec 19 | 25,036 | -2,298 | 5,436 | 0 |
30 Sep 19 | 28,970 | -3,859 | 6,073 | 0 |
30 Jun 19 | 29,505 | -4,084 | 6,154 | 0 |
31 Mar 19 | 29,970 | -4,551 | 6,470 | 0 |
31 Dec 18 | 29,526 | -3,153 | 6,414 | 0 |
30 Sep 18 | 29,325 | -3,237 | 6,312 | 0 |
30 Jun 18 | 28,868 | -2,551 | 5,788 | 0 |
31 Mar 18 | 27,784 | -2,011 | 5,863 | 0 |
31 Dec 17 | 26,958 | -3,149 | 5,686 | 0 |
30 Sep 17 | 26,234 | -2,287 | 5,487 | 0 |
30 Jun 17 | 26,258 | -1,767 | 5,283 | 0 |
31 Mar 17 | 26,329 | -845 | 5,492 | 0 |
31 Dec 16 | 26,120 | -735 | 5,615 | 0 |
30 Sep 16 | 26,264 | -503 | 5,560 | 0 |
30 Jun 16 | 25,920 | -140 | 5,481 | 0 |
31 Mar 16 | 26,029 | -849 | 5,288 | 0 |
31 Dec 15 | 25,663 | -1,521 | 8,214 | 0 |
30 Sep 15 | 25,818 | -1,604 | 8,305 | 0 |
30 Jun 15 | 26,394 | -1,906 | 5,272 | 0 |
31 Mar 15 | 26,923 | -1,797 | 5,680 | 0 |
31 Dec 14 | 27,970 | -1,774 | 8,897 | 0 |
30 Sep 14 | 27,719 | -1,468 | 9,082 | 0 |
30 Jun 14 | 29,365 | -829 | 5,756 | 0 |
31 Mar 14 | 30,620 | -1,133 | 9,011 | 0 |
31 Dec 13 | 32,284 | -1,822 | 8,913 | 0 |
30 Sep 13 | 33,508 | -769 | 8,578 | 0 |
30 Jun 13 | 34,311 | -174 | 5,181 | 0 |
Quality Earnings: 526853 has a large one-off gain of ₹2.2B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 526853 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 526853 has become profitable over the past 5 years, growing earnings by 72.1% per year.
Accelerating Growth: 526853 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 526853 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: 526853's Return on Equity (5.8%) is considered low.